Trulieve Cannabis Corp.
10.42USD
-0.5000 (-4.58%)
Not enough data yet
A reading needs 5 members, each at least 14 days old with a track record on this site (simulated portfolios and calls), who shared a take in the last 30 days; 2 of them need a strong record.
Sign in to share your take on TRLV.
Revenue
| (USD) | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 |
|---|---|---|---|---|---|---|
| FY | 1.2B | 1.1B | 1.2B | 1.2B | 1.0B | 936.4M |
| Q1 | 317.7M | 285.2M | 297.6M | 297.8M | 286.8M | — |
| Q2 | 313.8M | 281.8M | 303.4M | 302.1M | 271.0M | — |
| Q3 | 295.4M | 275.2M | 284.3M | 288.2M | 221.6M | — |
| Q4 | 298.5M* | 287.0M* | 301.1M* | 293.1M* | 229.5M | — |
Revenue
| (USD) | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 |
|---|---|---|---|---|---|---|
| FY | -.950 | -2.28 | -.790 | -.580 | -1.82 | .557 |
| Q1 | -.160 | -.180 | -.160 | -.160 | .012 | — |
| Q2 | -.090 | -1.80 | -.040 | -.084 | -2.11 | — |
| Q3 | -.380 | -.120 | -.320 | -.150 | .070 | — |
| Q4 | -.432* |
Fiscal period: Reported, Estimated. Reported figures: SEC filings (EDGAR). Estimates are sell-side consensus for periods that have not reported. Cells marked * were synthesized from the annual filing less the year-to-date figures, because the quarter was not filed on its own. Earnings per share are restated onto today's share basis, so a period before a stock split is comparable with the ones after it.
Revenue to net income
| -.184* |
| -.329* |
| -.228* |
| .075 |
| — |
Debt level and coverage